Tip os
Log ind
38642339.jpg
Foto: Mikkel Berg Pedersen

Novo’s US head is ready for turnaround

Top picks in English:

The head of Novo Nordisk’s North American business, Jakob Riis, has made the necessary changes to facilitate a turnaround in his first five months in the job. He now has the freedom and room to maneuver that should lead to twice as big a share of the market for the group's major insulin hope.


BY STEFAN SINGH KAILAY
Offentliggjort 08.02.17 kl. 16:08

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo chief: ”This is data the world has never seen before”

Mads Krogsgaard Thomsen Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Veloxis expands to China and Canada

Top picks in English:

The Danish pharmaceutical company Veloxis has entered more new agreements to market its main product Envarsus XR in both Canada and China.

Lundbeck executive: I knew FDA had another opinion

Top picks in English:

It is yet uncertain whether Lundbeck, for the third time, will try to win an updated label for antidepressant Trintellix in the US, says Anders Gersel Pedersen, Lundbeck’s executive vice president for research and development. Last week's rejection from FDA came as no surprise to him.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Onxeo raises EUR 15m in stock offering

Top picks in English:

The French-Danish biotech company Onxeo has raised EUR 15 million (USD 16.73 million) in a recently completed capital increase. The goal was EUR 12 million (USD 13.39 million), but the fundraising brought the company’s management a pleasant surprise.

Forsiden lige nu

MedWatch-indeks: Lundbeck til tops i nyhedsfattig uge

Nasdaq København2.jpg Medicinal & Biotek:

Både Novo Nordisk og Genmab høstede positiv omtale i ugens løb, men alligevel er det Lundbeck, der løber med denne uges topplacering i MedWatch-indekset.

Dansk medicoselskab går konkurs

Medico & Rehab:

Direktøren for LJ Medical Nordic havde satset på, at han kunne vende skuden i selskabet efter flere års svingende resultater, men de planer er ikke lykkes, og selskabet er nu meldt konkurs.

Sanofi indgår milliardaftale med Novo-partner

Medicinal & Biotek:

Den franske medicinalkoncern Sanofi har skrevet under på en aftale med et belgisk biotekselskab, som også arbejder sammen med Novo Nordisk. Aftalen har en potentiel værdi af flere milliarder.

Coloplast-konkurent køber ind i USA

Medico & Rehab:

En af Coloplasts konkurrenter, som Novo A/S for nyligt investerede i, har været ude og købe ind på det amerikanske marked for et trecifret millionbeløb.

FDA giver grønt lys til ny Lantus-kopi

Medicinal & Biotek:

Konkurrencen på markedet for basalinsulin spidser til endnu en gang med godkendelsen af en ny kopi af Sanofis bestseller Lantus. En eventuel lancering afhænger dog af domstolene.

Nordjyske liftselskaber taber pusten

Medico & Rehab:

Efter fire års fremdrift måtte den nordjyske liftproducent Cama Lift notere tilbagegang i 2016. Den ligeledes nordjyske producent af løfteteknik, BC Lift, er også ramt på bundlinjen.

ANNONCE


ANNONCE